A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

@article{Lee2014ARP,
  title={A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.},
  author={Oukseub Lee and Katherine Page and David Ivancic and Irene B Helenowski and Vamsi Parini and Megan Sullivan and Julie Margenthaler and Robert Treat Chatterton and Borko D. Jovanovic and Barbara K. Dunn and Brandy M. Heckman-Stoddard and Kathleen Foster and Miguel Muzzio and Julia Shklovskaya and Silvia Skripkauskas and Piotr Kulesza and Dale Green and Nora M. Hansen and Kevin P. Bethke and Jacqueline Sara Jeruss and Raymond C. Bergan and Seema A Khan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 14},
  pages={3672-82}
}
PURPOSE Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). METHODS Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…